Table 4.
Performance of European and US Second-Tier Immunoblot Assays
| No. Positive (%) |
||||||
|---|---|---|---|---|---|---|
| European IgM IBa | European IgG IBa | European IgM or IgG IBa | US IgM IBb | US IgG IBb | US IgM or IgG IBb | |
| Patients with Lyme borreliosis acquired in Europe (n = 64) | 34 (53) | 43 (67) | 52 (81) | 16 (25) | 32 (50) | 37 (58) [.007] |
| Erythema migrans (n = 20) | 7 (35) | 7 (35) | 11 (55) | 2 (10) | 2 (10) | 4 (20) [.05] |
| Lyme neuroborreliosis (n = 15) | 12 (80) | 9 (60) | 13 (87) | 6 (40) | 6 (40) | 8 (53) [.11] |
| Lyme arthritis (n = 15) | 10 (67) | 13 (87) | 14 (93) | 4 (27) | 10 (67) | 11 (73) [0.33] |
| Acrodermatitis chronica atrophicans (n = 14) | 5 (36) | 14 (100) | 14 (100) | 4 (29) | 14 (100) | 14 (100) [1.00] |
| Healthy control subjects from nonendemic area (n = 100) | 9 (9) | 0 (0) | 9 (9) | 0 (0) | 0 (0) | 0 (0) [.003] |
Bracketed numbers represent the P values for the comparison with combined results obtained using European IgM and IgG immunoblots.
Abbreviations: IB, immunoblot; IgG, immunoglobulin G; IgM, immunoglobulin M.